Advertisement

Volume 129, Issue 5

Cover Figure: Role of heat shock protein 90 in B-cell receptor signaling in Burkitt lymphoma. See the article by Walter et al.

WASHINGTON, February 2, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

BCR-ABL–specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors
Targeting the tumor-specific junction sequence produced by the BCR-ABL fusion has long been an attractive strategy. In a first-in-human study, Comoli et al demonstrate clinical benefit from infusions of p190BCR-ABL neoantigen–specific T cells to patients with active Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL).

G-CSF-induced sympathetic tone provokes fever and primes anti-mobilizing functions of neutrophils via PGE2
Kawano et al show that neutrophils, by producing prostaglandin E2 (PGE2), regulate hematopoietic stem cell mobilization and cause fever.

HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling
Walter et al demonstrate an association between heat shock protein 90 (HSP90) and spleen tyrosine kinase (SYK) as a critical upstream component in tonic BCR signaling of Burkitt lymphoma (BL). They propose HSP90 as a novel therapeutic target in BL.

Widespread and dynamic translational control of red blood cell development
Alvarez-Dominguez et al present mechanisms governing the precise but highly dynamic translational control of protein synthesis during red blood cell development.

Autophagy, a key mechanism of oncogenesis and resistance in leukemia
In their Blood Spotlight review, Auberger and Puissant highlight recent findings on the impact of autophagy on leukemic transformation of hematopoietic stem cells and discuss the role of autophagy in resistance to chemotherapy

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
A panel of experts on hairy cell leukemia provides consensus recommendations pertaining to the workup, management, and evaluation of response in this disease.

Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma
Up to 50% of patients with Hodgkin lymphoma and diffuse large B-cell lymphoma relapse and require additional therapy. This Evidence-Based Focused Review evaluates the role of surveillance imaging in relapse detection and its impact on survival.

How I treat FLT3-mutated AML
In their How I treat article about FLT3-mutated acute myeloid leukemia (AML), Pratz and Levis present representative clinical cases and offer thoughts on the therapeutic management of this condition.

An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
This paper describes an elegantly designed, fully humanized, novel T-cell–engaging bispecific antibody construct for the treatment of AML by targeting CLL-1.

GVHD prevents NK-cell–dependent leukemia and virus-specific innate immunity
The authors present novel findings demonstrating that graft-versus-host disease (GVHD) negatively affects NK cell recovery through competition between donor T cells and NK cells for interleukin-15 (IL-15). The NK cell regenerative defect can be corrected with IL-15.

A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD
Socié et al report on a phase 3 multicenter randomized trial comparing inolimomab with the standard of care (antithymocyte globulin) for therapy of steroid-refractory acute GVHD.

This week's complete table of contents

Why Submit to Blood?

 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.